Imprimis Pharmaceuticals Sells Pennsylvania Facility and Sinus Assets

Industry Reports
Typography

Imprimis Pharmaceuticals, Inc , an ophthalmology-focused pharmaceutical company, announced it has entered into an agreement to sell its Folcroft, Pennsylvania facility and sinus related assets for $450,000.  

The closing of this transaction is expected to occur on or around July 17, 2017, subject to customary terms and conditions. 

Mark L. Baum, CEO of Imprimis said, "We are committed to focusing on our core growing ophthalmology business.  The markets we serve with proprietary products in ophthalmology, including our cataract surgery portfolio, medications used in post-LASIK surgery care, our Simple Drops glaucoma program we recently launched and the upcoming launches we have planned to serve dry eye disease patients and other markets in ophthalmology should allow us to build a profitable and valuable company."  Baum continued, "In furtherance of this focus, we entered into an agreement to sell our Folcroft facility and exit the sinus space.  We believe this is an important step towards reducing non-strategic overhead expenses and focusing internal resources on strengthening our growing ophthalmology business."

About Imprimis Pharmaceuticals
Imprimis Pharmaceuticals, Inc. is a pharmaceutical company dedicated to producing and dispensing high quality innovative medications in all 50 states.  The company's unique business model increases patient access and affordability to many critical medicines.  Headquartered in San Diego, California, Imprimis owns and operates three production and dispensing facilities located in California, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisRx.com. 

Investor Contact:
Andrew Boll
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.
858-704-4042

Market Movers

Rogers Corporation

NYQ : ROG - 22 Aug, 10:33am
113.20
+0.56 (+0.50%) After Hours:
Open 112.82 Mktcap 2.06B
High 114.19 52wk Hight 123.38
Low 112.22 52wk Low 51.98
Vol 22304 Avg Vol 121844
Eps 5.55 P/e 27.30
Currency: USD

Banco Santander, S.A. Sponsored

NYQ : SAN - 22 Aug, 10:35am
6.475
+0.035 (+0.543%) After Hours:
Open 6.430 Mktcap 99.59B
High 6.480 52wk Hight 6.990
Low 6.420 52wk Low 4.190
Vol 874829 Avg Vol 6.94M
Eps 0.490 P/e 12.171
Currency: USD

Merck & Company, Inc. (new)

NYQ : MRK - 22 Aug, 10:35am
62.13
+0.16 (+0.26%) After Hours:
Open 61.97 Mktcap 169.45B
High 62.34 52wk Hight 66.80
Low 61.92 52wk Low 58.29
Vol 925893 Avg Vol 8.24M
Eps 3.87 P/e 33.64
Currency: USD

Johnson & Johnson

NYQ : JNJ - 22 Aug, 10:34am
133.35
-0.10 (-0.07%) After Hours:
Open 133.27 Mktcap 357.91B
High 133.85 52wk Hight 137.08
Low 132.90 52wk Low 109.32
Vol 742786 Avg Vol 5.52M
Eps 7.18 P/e 22.56
Currency: USD

Pfizer, Inc.

NYQ : PFE - 22 Aug, 10:35am
32.91
+0.15 (+0.46%) After Hours:
Open 32.76 Mktcap 195.73B
High 33.00 52wk Hight 35.38
Low 32.70 52wk Low 29.83
Vol 1.78M Avg Vol 18.42M
Eps 2.56 P/e 24.07
Currency: USD

Direxion Daily 10-Yr Treasury B

PCX : TYO - 22 Aug, 10:04am
13.65
+0.04 (+0.29%) After Hours:
Open 13.63 Mktcap
High 13.65 52wk Hight 16.29
Low 13.63 52wk Low 12.79
Vol 221 Avg Vol 4272
Eps P/e
Currency: USD